博济医药(300404.SZ)：FCZR获得药物临床试验批准通知书

Core Viewpoint - Boji Pharmaceutical has received approval from the National Medical Products Administration for its clinical trial of the new drug "FCZR," which targets ear fungal infections and offers significant clinical advantages over existing treatments [1] Company Summary - Boji Pharmaceutical (300404.SZ) has announced the approval of its drug "FCZR" for clinical trials, indicating progress in its product development pipeline [1] - The drug is classified as a modified new drug of category 2.2/2.4, optimized for formulation, prescription process, administration route, and indications [1] Industry Summary - Ear fungal disease is a common infectious condition in otolaryngology, particularly prevalent in hot and humid seasons and regions, often recurring and difficult to cure [1] - Currently, there are no approved drugs for this condition in both domestic and international markets, highlighting a potential market opportunity for FCZR [1]